Voyager Therapeutics (VYGR) Other financing activities (2017 - 2026)
Voyager Therapeutics (VYGR) posted Other financing activities of $294000.0 for Q1 2026, up 276.05% sequentially from -$167000.0 in Q4 2025, and up 258.54% YoY from $82000.0 in Q1 2025.
Voyager Therapeutics (VYGR) Other financing activities (2017 - 2026) Analysis & Trends
Voyager Therapeutics has reported Other financing activities for 10 years, with the latest figure at $294000.0 in Q1 2026.
- Quarterly Other financing activities rose 258.54% year-over-year to $294000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $479000.0 (up 22.19% YoY) and the FY2025 annual result came in at $267000.0, down 31.19% from the prior year.
- Other financing activities climbed to $294000.0 in Q1 2026 per VYGR's latest filing, from -$167000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $1.2 million in Q2 2023 and troughed at -$167000.0 in Q4 2025.
- A 5-year average of $214375.0 and a median of $80000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2025: Other financing activities soared 2666.67% in 2023, then tumbled 1092.86% in 2025.
- Over 5 years, Other financing activities stood at $27000.0 in 2022, then dropped by 14.81% to $23000.0 in 2023, then slumped by 160.87% to -$14000.0 in 2024, then sank by 1092.86% to -$167000.0 in 2025, then jumped by 276.05% to $294000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $294000.0, -$167000.0, and $352000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57,000.00 |
| Jun 30, 2026 | 57,000.00 |
| Mar 31, 2026 | 294,000.00 |
| Mar 31, 2026 | 294,000.00 |
| Dec 31, 2025 | -167,000.00 |
| Dec 31, 2025 | -167,000.00 |
| Jun 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 352,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | -14,000.00 |
| Dec 31, 2024 | -14,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Dec 31, 2023 | 23,000.00 |